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Abstract
Purpose of review—The Centers for Disease Control and Prevention (CDC) recently 
transitioned from ventilator-associated pneumonia surveillance to ventilator-associated event 
(VAE) surveillance in adult inpatient settings. Since the transition, several modifications have 
been made to improve surveillance methods, and there is a growing body of data regarding the 
epidemiology, risk factors, and preventability of VAEs.
Recent findings—The VAE surveillance definition algorithm is based on objective criteria and 
includes three tiers: Ventilator-Associated Conditions, Infection-related Ventilator-Associated 
Complications, and Possible and Probable VAP. VAE surveillance expands the purview of 
surveillance beyond pneumonia alone to include additional complications of mechanical 
ventilation. Most VAEs are caused by pneumonia, pulmonary edema, atelectasis, and/or acute 
respiratory distress syndrome. VAEs are associated with adverse outcomes including prolonged 
mechanical ventilation, longer intensive care and hospital lengths-of-stay, and higher mortality 
rates. Studies to date suggest that minimizing sedation and optimizing fluid management can 
reduce VAE rates.
Summary—We review CDC’s recent updates on VAE surveillance definitions, methods, and 
tools, and provide an overview of the growing evidence base for VAE as a patient safety measure. 
Further work is needed to affirm and extend current knowledge about how best to prevent VAEs.
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Introduction
Ventilator-associated pneumonia (VAP) is a common and morbid complication of 
mechanical ventilation.[1] Tracking VAP at the national level has proved challenging due to 
the lack of valid, reliable definitions. The Centers for Disease Control and Prevention (CDC) 
convened a working group of critical care and healthcare epidemiology experts in 2011 to 
help develop a new approach to surveillance in mechanically ventilated patients. This new 
approach, called “Ventilator-Associated Event” (VAE) surveillance, was implemented in 
CDC’s national healthcare-associated infection surveillance system, the National Healthcare 
Safety Network (NHSN), in January 2013.[2]
VAE surveillance definitions were developed to increase the reliability of surveillance data, 
reduce the burden of surveillance in healthcare facilities, and enhance the utility of 
surveillance data for improving patient safety.[2, 3] The definitions are based on objective 
criteria, and detect a broad range of clinical events, including VAP.[4, 5] There are three 
VAE tiers (Figure). The first and foundational definition specified in the algorithm is 
“Ventilator-Associated Condition” (VAC). Criteria for this condition are met when a patient 
experiences ≥2-days of worsening oxygenation following ≥2-days of stability on a 
ventilator, defined by changes in the daily minimum fraction of inspired oxygen (FiO2) or 
positive end-expiratory pressure (PEEP). The second definition, “Infection-related 
Ventilator-Associated Complication” (IVAC), is defined by VAC plus an abnormal 
temperature or white blood cell count; and the start of a new antimicrobial agent continued 
for ≥4 days. The third definition tier consists of “Possible VAP” and “Probable VAP,” and is 
defined by IVAC plus laboratory and/or microbiological evidence of infection.[6]
Since the inception of VAE surveillance in the NHSN, additional studies have been 
published confirming the limitations of traditional VAP definitions for public reporting and 
the consequent need for a more objective approach to surveillance.[7–9] In addition, users 
have sent feedback to CDC regarding operational challenges with the VAE definitions and 
surveillance methods. Based on this feedback and input from the expert working group that 
helped develop the VAE definitions, CDC implemented modifications to address the most 
significant of these challenges. Finally, multiple investigators in the United States and other 
countries have undertaken studies to address VAE knowledge gaps, including the correlation 
of VAE with traditional VAP surveillance, clinical correlates of VAE surveillance events, 
risk factors for VAEs, and strategies to prevent VAEs. This article provides an update and 
rationale for recent changes to VAE surveillance and reviews the current published literature 
on VAE.
Patients eligible for inclusion in VAE surveillance
When VAE surveillance was implemented in the NHSN, surveillance was restricted to adult 
patients (age ≥ 18 years). This restriction was instituted because data were lacking on use of 
streamlined, objective VAE or VAP definitions in pediatric populations. However, because 
other surveillance in the NHSN’s “Device-Associated Module” is based on healthcare 
facility locations rather than on patient age or other patient-level characteristics, VAE’s 
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patient age restriction created logistical challenges for users. For example, in some cases 
mechanically ventilated pediatric patients may be cared for in adult intensive care units. 
According to the original VAE surveillance protocol, these patients were excluded from 
VAE surveillance, although they were included in counts of ventilator and patient days. 
CDC therefore decided to eliminate the patient-level age restriction and make VAE 
surveillance location-based, restricted to adult inpatient locations only, starting in 2014.[10]
Ventilator settings used in meeting the VAC definition
Some users of the NHSN’s VAE surveillance protocol in 2013 reported that differences in 
providers’ preferred mechanical ventilation management strategies were triggering some 
VAEs. These VAEs were typically detected due to changes in PEEP settings occurring in 
the 0–5 cm H2O range: for example, a patient may have been on PEEP of 0 cm H2O for a 
period of days based on the management preferences of one provider, and then be placed on 
a PEEP setting of 5 cm H2O for a period of additional days due to transition of care to a new 
provider with a preference for maintaining all patients on some degree of PEEP. The change 
in provider and consequent increase in PEEP would then result in a VAC. To minimize 
these occurrences, CDC implemented a protocol modification in August 2013 to specify that 
for surveillance purposes, PEEP settings of 0–5 cm H2O would be considered equivalent 
(i.e., the daily minimum PEEP setting would be considered to be 5 cm H2O for any day 
where the lowest PEEP settings ranged between 0 and 5 cm H2O).[6, 11] As a consequence 
of this modification, daily minimum PEEP settings must now rise to ≥ 8 cm H2O for ≥ 2 
days to trigger a VAC.
CDC also responded to concerns that VAE detection might vary when using minute-by-
minute or hour-by-hour ventilator settings electronically extracted from ventilators rather 
than manually documented settings charted by respiratory therapists and / or nurses. 
Researchers in the Netherlands have provided some support for this concern.[12] They 
retrospectively compared VAE detection in 2 ICUs using daily minimum PEEPs and FiO2s 
derived from minute-by-minute electronic ventilator extracts versus hourly values charted 
by clinicians. They found that the two methods detected a similar absolute number of VACs 
but only about 75% of the events were common to both methods. Consequently, the revised 
2014 protocol now defines the daily minimum setting to be “the lowest setting of PEEP or 
FiO2 during a calendar day that is maintained for at least 1 hour.”[6, 10] This new rule might 
also obviate the concern that some hospitals could “game” VAE definitions by dropping the 
PEEP and FiO2 to minimal levels for a minute per day. Under the original VAE rules, this 
clinically meaningless manipulation of ventilator values would keep patients’ daily 
minimum PEEPs and FiO2s static and thereby prevent any VAEs from being detected.
Antimicrobial agents eligible for meeting the IVAC definition
The definition for IVAC, like that for VAC, was not developed for detection of respiratory 
tract infections specifically but was intended to capture a broad range of potentially 
infectious conditions associated with a deterioration in respiratory status.[2] The initial list 
of eligible antimicrobial agents was therefore broad. It included drugs such as daptomycin 
and fidaxomicin that are not used to treat respiratory infections and numerous oral agents 
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that would typically not be used to treat respiratory infections in mechanically-ventilated 
patients. The inclusion of such drugs caused confusion among NHSN users, and therefore, 
with input from the expert working group, CDC removed drugs that are typically not used to 
treat respiratory infections from the list of eligible agents.[6, 10]
Defining purulent respiratory secretions to meet the Possible and Probable 
VAP definitions
To meet the Possible or Probable VAP definitions, laboratory and/or microbiological 
evidence of infection is required. For Possible VAP, patients must have purulent respiratory 
secretions (defined as ≥ 25 white blood cells and ≤ 10 epithelial cells per low power field on 
Gram stain) or a positive culture of respiratory secretions. For Probable VAP, patients must 
have purulent secretions plus a positive culture of respiratory secretions (meeting or 
exceeding specified growth thresholds). There are other criteria for Legionella and selected 
respiratory viruses as well as criteria for lung histopathology to satisfy the Probable VAP 
definition, but these are infrequently used.
Some hospitals noted that they were unable to use the purulent respiratory secretions 
criterion as originally specified because their clinical laboratories do not routinely report 
epithelial cell counts or because of other variations in laboratory practices. CDC 
consequently modified the VAE surveillance protocol to provide additional flexibility within 
this criterion.[6, 10]
Electronic tools for surveillance
For new users in particular, the VAE algorithm can seem complex and confusing. To help 
users learn the definitions, CDC developed a web-based “VAE Calculator.”[13] The 
Calculator, which was updated recently to reflect the 2014 protocol modifications, allows 
users to enter VAE data elements for a single patient and receive a VAE determination along 
with an explanation regarding why the determination was made. Patient identifiers are not 
entered into the Calculator; it is primarily intended to be an educational tool, and does not 
store patient data or submit data to the NHSN.
One of CDC’s goals is to help healthcare facilities automate VAE detection. CDC has 
embarked on two initiatives to facilitate this goal: development of a web service approach 
and creation of a synthetic patient dataset. The web service, which is currently in a limited 
pilot implementation, allows an Electronic Health Record (EHR) system or a local infection 
surveillance system to submit de-identified data from a population of patients to a 
centralized server. The server receives the data and applies the VAE definitions, returning to 
the sender a list of all the patient records meeting the various VAE criteria. The sender 
maintains a linkage between the patient records submitted and the actual patient information, 
insuring that no Personally Identifiable Information leaves the sender’s site.
The web service may be used in two ways. Electronic systems may utilize the service by 
making routine calls to the web service for case determinations. This obviates the need to 
code for VAE definitions within EHRs or infection surveillance software. The web service 
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can also be used as a development and validation tool by vendors that prefer to code for 
VAE detection themselves rather than calling on the web service. Developers that opt for 
this pathway may validate their coding by submitting test data to the web service. This is 
important to ensure consistency and accuracy between different VAE implementations. 
Errors that occur in this coding process may lead to systematic inaccuracies. The web 
service provides a single source of truth for developers to test themselves against. As a 
complement to the web service, CDC is working to create a synthetic patient dataset that 
vendors can use to test their VAE coding. The dataset is anticipated to be available in 2015.
CDC is working with partners to develop Clinical Document Architecture messages to 
enable facilities to electronically report VAEs to the NHSN. At present, users need to 
manually enter VAEs into the NHSN web-based portal. Once the Implementation Guide is 
ready, EHR developers and proprietors of commercial infection control surveillance 
software will be able to submit events electronically and automatically.
Addressing VAE knowledge gaps: recent additions to the scientific 
literature
Recent studies have deepened our knowledge of VAE epidemiology, morbidity, risk factors, 
and potential prevention strategies. Klompas and colleagues characterized the incidence, 
microbiology, and attributable morbidity of VAEs amongst 20,356 consecutive episodes of 
mechanical ventilation in a large academic center.[14] VAEs were detected in 5.6% of 
episodes. Of these, 38% met criteria for IVAC, 12% met criteria for Possible VAP, and 11% 
met criteria for Probable VAP. The risk for VAC was highest in medical, surgical, and 
thoracic units; the risk was lowest in cardiac and neuroscience units. The most frequently 
isolated organisms in patients with Possible or Probable VAP were Staphylococcus aureus 
(29%), Pseudomonas aeruginosa (14%), and Enterobacter species (7.9%). All VAE tiers 
were associated with prolongation of mechanical ventilation and hospital length of stay as 
well as higher hospital mortality risk compared to matched patients without VAEs. IVAC 
was associated with longer durations of mechanical ventilation and hospital lengths-of-stay 
compared to VAC alone but there was no difference in mortality risk between tiers.
Dutch investigators affirmed that VAC surveillance detects a different population of patients 
than traditional VAP surveillance.[12] They retrospectively applied VAE definitions to a 
cohort of patients and compared them to VAPs that were prospectively identified by 
research nurses using classical clinical, radiographic, and microbiologic criteria. The Dutch 
investigators found limited overlap between VAC and VAP. Only 44% of patients with 
clinical VAP met VAC criteria and only 9% of patients with VAC met clinical criteria for 
VAP. The investigators analyzed why patients with VAP did not meet VAC criteria. The 
most common reason (76% of VAC-negative cases) was because VAP patients’ ventilator 
settings did not increase despite their ostensible pulmonary infections.
The Dutch team also reviewed the charts of 81 patients with VAC to identify possible 
clinical etiologies for these patients’ respiratory deterioration. They found that 40/81 (50%) 
events were associated with respiratory tract infections, mucous plugging, and/or aspiration; 
39/81 (48%) cases were associated with volume overload, heart failure, and/or pleural 
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effusion; and 30/81(37%) cases were associated with sepsis, pneumothorax, abdominal 
distension, or acute neurological events. There was no apparent etiology for VAC in 10/81 
(12%) cases. These findings mirror the results of previous investigations.[4, 5]
Investigators in four studies have found relatively limited overlap between VAC and 
clinically-defined VAP.[4, 12, 15, 16] Most VACs are attributable to pneumonia, pulmonary 
edema, atelectasis, and/or acute respiratory distress syndrome.[4, 5, 12] This implies that 
preventing VAEs will require broadening ventilator bundles to include interventions that 
target all of these conditions. Fortunately, the interventions needed to prevent these 
conditions are congruent with many of the emerging best practices endorsed by critical care 
societies such as daily spontaneous awakening and breathing trials, maintaining euvolemia, 
minimizing blood transfusions, ventilating patients with low tidal volumes, and encouraging 
early mobility.[17] VAE surveillance therefore offers intensivists a metric to monitor the 
impact of these best practices and a means to motivate care teams to optimize their 
performance. [3] [18]
Investigators are now working to confirm that these best practices can indeed prevent VAEs. 
Lewis and colleagues organized a case-control study to identify risk factors associated with 
VAC and IVAC.[19] They matched 110 patients with VAC to 110 patients without VAC. 
Of the 110 patients with VAC, 38 met criteria for IVAC. They then evaluated a host of 
potentially modifiable care factors including head of bed elevation, oral care with 
chlorhexidine, mode of mechanical ventilation, tidal volume, frequency of spontaneous 
awakening and breathing trials, net daily fluid balance, use of blood products, choice of 
sedatives, and route of nutrition. They found that mandatory modes of mechanical 
ventilation and positive fluid balances were risk factors for VAC and early administration of 
benzodiazepines was a risk factor for IVAC. These findings support the importance of 
sedation, fluid management, and ventilator settings in the design of bundles to prevent 
VAEs.
Emerging studies on VAE prevention highlight the importance of minimizing sedation and 
optimizing fluid balance. We are aware of at least 3 studies evaluating the preventability of 
VAEs. The first study was published by the Canadian Critical Care Trials Group.[15] They 
retrospectively evaluated VAC rates and risk factors for VAC amongst 1330 patients 
sampled intermittently from 11 ICUs enrolled in a two-year prospective effort to increase 
adoption of best practices for the care of ventilated patients. Over the study period, there was 
a modest increase in the performance of recommended measures and a corresponding 
modest decrease in the risk of VAC. On multivariable regression, the percentage of days 
with spontaneous awakening trials was associated with lower VAC risk (OR 0.93 per 1% 
increase in percent of days with spontaneous awakening trials, 95% CI 0.87–1.00).
The second study assessed the impact of enhanced fluid management on VAP and VAC 
risk. Dessap and colleagues retrospectively applied VAC definitions to data from a 
prospective randomized trial of the benefit of daily B-type Natriuretic Peptide (BNP) levels 
to guide fluid management during weaning from mechanical ventilation.[16] They found 
that daily BNP measurements were associated with more negative fluid balances, fewer days 
of mechanical ventilation, and significant decreases in both VAC (approximately 52% fewer 
Magill et al. Page 6
Curr Opin Infect Dis. Author manuscript; available in PMC 2015 November 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
VACs in the intervention group as compared to the usual care group, p=0.02) and VAP 
(approximately 48% fewer VAPs in the intervention group, p=0.03).
The third study of VAE prevention is the CDC Prevention Epicenters Wake Up and Breathe 
Study. This is a prospective multicenter evaluation of the benefit of paired daily spontaneous 
awakening and spontaneous breathing trials on the impact of VAEs (ClinicalTrials.gov 
Identifier NCT 01583413). Results from this study are expected later this year.
Conclusion
The introduction of VAE surveillance in the NHSN in 2013 was followed by refinements 
and clarifications to the VAE protocol in response to user feedback. CDC also introduced an 
expanding suite of electronic tools to help providers and hospitals implement VAE 
surveillance. Recent investigations have confirmed the strong association between VAEs 
and adverse outcomes and are starting to provide data on how best to prevent VAEs.
VAE prevention begins with recognition that there is limited overlap between VAC and 
VAP. Most VACs are triggered by one or more of four conditions: pneumonia, pulmonary 
edema, atelectasis, and / or acute respiratory distress syndrome. Minimizing patient sedation 
and optimizing fluid management both appear to be potent strategies to prevent VACs. 
Additional work to define and implement bundles optimized to prevent VAEs holds further 
promise to improve outcomes for mechanically ventilated patients.
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Key points
• Surveillance for ventilator-associated events (VAE) was implemented in CDC’s 
National Healthcare Safety Network in January 2013; improvements and 
clarifications to the surveillance protocol have recently been made.
• CDC continues to work on developing electronic tools to assist NHSN users in 
conducting VAE surveillance.
• Studies have shown that VAEs are strongly associated with adverse outcomes.
• Recent additions to the VAE scientific literature are beginning to address 
important knowledge gaps, including the extent to which VAEs are preventable.
Magill et al. Page 9
Curr Opin Infect Dis. Author manuscript; available in PMC 2015 November 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure. 
Heading: Ventilator-associated event surveillance definition algorithm
Legend: None
Source: Centers for Disease Control and Prevention. Ventilator-Associated Event Protocol. 
Available at: http://www.cdc.gov/nhsn/acute-care-hospital/vae/index.html. Accessed March 
25, 2014.
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